A novel noninvasive index for nonalcoholic steatohepatitis: A pilot study

Biomarkers

Volumn 18, Issue 7, 2013, Pages 607-613

  Polyzos, Stergios A ^a   Kountouras, Jannis ^a   Slavakis, Aristeidis ^a   Zafeiriadou, Efthimia ^a   Patsiaoura, Kalliopi ^a   Katsiki, Evangelia ^a   Zavos, Christos ^a   Papatheodorou, Athanasios ^b   Terpos, Evangelos ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Erythrocyte sedimentation rate; Homocysteine; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Serum glutamic oxaloacetic transaminase

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HOMOCYSTEINE;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PILOT STUDY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; GREECE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; ROC CURVE;

EID: 84888870308     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.838305     Document Type: Article

References (28)

1. Angulo P, Hui JM, Marchesini G, et al. (2007). The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846-54.
2. Cales P, Laine F, Boursier J, et al. (2009). Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 50:165-73.
3. Chalasani N, Younossi Z, Lavine JE, et al. (2012). The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005-23.
4. Deminice R, Portari GV, Marchini JS, et al. (2009). Effects of a low-protein diet on plasma amino acid and homocysteine levels and oxidative status in rats. Ann Nutr Metab 54:202-7.
5. Fan JG, Jia JD, Li YM, et al. (2011). Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010;18: 163-166). J Dig Dis 12:38-44.
6. Friedewald WT, Levy RI, Fredrickson DS. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502.
7. Guha IN, Parkes J, Roderick P, et al. (2008). Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47: 455-60.
8. Guha IN, Parkes J, Roderick PR, et al. (2006). Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 55:1650-60.
9. Katz A, Nambi SS, Mather K, et al. (2000). Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-10.
10. Kleiner DE, Brunt EM, Van NM, et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-21.
11. Kruger FC, Daniels CR, Kidd M, et al. (2011). APRI: A simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 101:477-80.
12. Matthews DR, Hosker JP, Rudenski AS, et al. (1985). Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-19.
13. Miller MH, Ferguson MA, Dillon JF. (2011). Systematic review of performance of non-invasive biomarkers in the evaluation of nonalcoholic fatty liver disease. Liver Int 31:461-73.
14. Palekar NA, Naus R, Larson SP, et al. (2006). Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 26:151-6.
15. Polyzos SA, Kountouras J, Patsiaoura K, et al. (2012a). Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Ann Hepatol 11:68-76.
16. Polyzos SA, Kountouras J, Zavos C. (2009). Nonalcoholic fatty liver disease: The pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 72:299-314.
17. Polyzos SA, Kountouras J, Zavos C, et al. (2012b). Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46:272-84.
18. Poynard T, Ratziu V, Charlotte F, et al. (2006). Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6:34.
19. Ratziu V, Bellentani S, Cortez-Pinto H, et al. (2010). A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53:372-84.
20. Ratziu V, Charlotte F, Heurtier A, et al. (2005). Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128:1898-906.
21. Shah AG, Lydecker A, Murray K, et al. (2009). Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7:1104-12.
22. Shimada M, Kawahara H, Ozaki K, et al. (2007). Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 102:1931-8.
23. Sumida Y, Yoneda M, Hyogo H, et al. (2011). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 46:257-68.
24. Tamimi TI, Elgouhari HM, Alkhouri N, et al. (2011). An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 54:1224-9.
25. Vernon G, Baranova A, Younossi ZM. (2011). Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274-85.
26. Younossi ZM, Jarrar M, Nugent C, et al. (2008). A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 18:1430-7.
27. Younossi ZM, Page S, Rafiq N, et al. (2011). A biomarker panel for nonalcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 21:431-9.
28. Zois CD, Baltayiannis GH, Bekiari A, et al. (2010). Steatosis and steatohepatitis in postmortem material from Northwestern Greece. World J Gastroenterol 16:3944-9.